SCHEMBL5540346

SCHEMBL5540346

[CH2]c1ccc(Oc2cccc(OC(F)(F)F)c2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.46
MEN1 O00255 1/20 0.46
MITF O75030 1/20 0.46
ALDH1A1 P00352 1/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46
GFER P55789 1/20 0.46
KMT2A Q03164 1/20 0.46
NLRP1 Q9C000 1/20 0.46
NOD2 Q9HC29 1/20 0.46
MAPK14 Q16539 1/20 0.44
SCN9A Q15858 3/20 0.44
CETP P11597 6/20 0.43
PTGES2 Q9H7Z7 1/20 0.42
GPR3 P46089 1/20 0.41
F2 P00734 1/20 0.40
F10 P00742 1/20 0.40
FURIN P09958 1/20 0.40
CHRM5 P08912 1/20 0.39
KIF11 P52732 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5544915 0.86 CETP (0.43) SMN1; SMN2MEN1MITFALDH1A1GAA
SCHEMBL5670014 0.85 CETP (0.54) SMN1; SMN2MEN1MITFALDH1A1GAA
SCHEMBL2096267 0.85 EPHX2 (0.44) MAPTSCN9AGPR3KIF11
SCHEMBL9589995 0.82 LTA4H (0.53) SMN1; SMN2MEN1MITFALDH1A1GAA
SCHEMBL9588167 0.82 LTA4H (0.53) SMN1; SMN2MEN1MITFALDH1A1GAA
SCHEMBL12260870 0.82 SMN1; SMN2 (0.46) SMN1; SMN2MEN1MITFALDH1A1GAA
SCHEMBL9589488 0.82 LTA4H (0.53) SMN1; SMN2MEN1MITFALDH1A1GAA
SCHEMBL4096194 0.82 ALDH1A1 (0.71) SMN1; SMN2MEN1MITFALDH1A1GAA
SCHEMBL22407023 0.82 AR (0.46) SMN1; SMN2MEN1MITFALDH1A1GAA
SCHEMBL14586638 0.82 HTT (0.49) SMN1; SMN2MEN1MITFALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 SMN1; SMN2 3985/4885MEN1 3295/4885MITF 4364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.